Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET
Company Participants
Hayleigh Collins – Senior Director, Corporate Communications and Investor RelationsSean P. Nolan – Chief Executive OfficerSukumar Nagendran – President and Head of R&DKamran Alam – Chief Financial Officer
Conference Call Participants
Kristen Kluska – Cantor FitzgeraldGil Blum – Needham and CompanyMaury Raycroft – JefferiesYanan Zhu – Wells FargoBiren Amin – Piper SandlerWhitney Ijem – Canaccord GenuityJack Allen – BairdJoon Lee – Truist SecuritiesSilvan Tuerkcan – CitizensMalcolm Hoffman – BMO Capital Markets
Operator
Greetings, and welcome to the Taysha Gene Therapies First Quarter 2025 Earnings Call.
At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Hayleigh Collins, Director, Head of Corporate Communications. Please go ahead.
Hayleigh Collins
Thank you. Good morning, and welcome to Taysha’s first quarter 2025 financial results and corporate update conference call.
Earlier today, Taysha issued a press release announcing financial results for the first quarter ended March 31, 2025. A copy of this press release is available on the company’s website and through our SEC filings.
Joining me on today’s call are Sean Nolan, Taysha’s Chief Executive Officer; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks.
Please note that on today’s call, we will be making forward-looking statements, including statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in the patient’s dose to-date in clinical trials to positively impact quality of life and alter the course
